Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
Social Determinants of Health and Prevention of Cardiovascular Disease
Research demonstrates that socioeconomic inequalities are "strong determinants" of cardiovascular risk throughout the world.
Members of the writing committee for the American College of Cardiology/American Heart Association 2019 Guideline on Primary Prevention of Cardiovascular Disease incorporated throughout the guideline consideration of how social determinants of health may impact the efficacy of specific guidance and prescriptions for an individual patient. ACC/AHA recommends that clinicians revisit these considerations at each follow-up visit.
Considerations include but are not limited to socioeconomic and educational status as well as cultural, home, and employment environments. The slides below highlight examples of considerations cited by the ACC/AHA for 7 health domains.
First Rivaroxaban Generics (2.5 mg) Get FDA Approval
The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.
First Rivaroxaban Generics (2.5 mg) Get FDA Approval
The first low-dose rivaroxaban generic tablets to be FDA approved lead a field crowded with applications for formulations of all the higher doses.
Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care
Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.
FDA Approves First Rapid-Acting Insulin Biosimilar for Diabetes: Daily Dose
Your daily dose of the clinical news you may have missed.
Obesity & Type 2 Diabetes: An Expert Discussion
In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.
Eli Lilly Expands Zepbound Access with New Vial Doses, Self-Pay Savings
Eli Lilly launched 2 new strengths of Zepbound single-dose vials for self-pay patients, and lowered the price of 2.5 mg and 5 mg vials.
Dupilumab Cardiometabolic Safety in Real-World Study of Atopic Dermatitis Supports Clinical Trial Evidence
Treatment of AD with dupilumab, compared with cyclosporine and methotrexate, was associated with significantly reduced risk of a wide range of CV outcomes at 1 year.